Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile

Ali et al., Journal of Pharmaceutical Research International, doi:10.9734/jpri/2020/v32i830468
May 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Review of the mechanisms of action, pharmacokinetics and toxicity of HCQ, recommending use as early as possible with a loading dose in 3-4 divided doses to minimize toxicity, and daily maintenance divided into two doses, continued until remission.
Ali et al., 29 May 2021, peer-reviewed, 8 authors.
This PaperHCQAll
Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile
Ahmed S Ali, Mahran S Abdel-Rahman, Riyadh S Almalikil, Abir S Mohamed, Khalid A Alfaifi, Abdelbabgi El. Fadil, Nagla A El-Shitany, Huda M Alkreathy
Journal of Pharmaceutical Research International, doi:10.9734/jpri/2020/v32i830468
Author RSA early joined the team to organize communication between researchers. He prepares the introduction. Author ASA assumed full supervision of the research with the assistance of all colleagues author MSAR prepared the side effects of the drug he also reviewed all that colleagues author ASM reviewed all clinical issues related to COVID 19 patients and their management she described in details cardiac toxicity of HCQ. Author AEF revised all sections related to the novel virus description and epidemiology. Author KAA collected and reviewed the pharmacokinetics of HCQ and its integration with the efficacy and safety issues. Author NAES participated actively in explaining the mechanism of HCQ. She also provided the summary and conclusion. Author HMA provided huge effort to edit the review, in a professional way regarding all aspects, language, reference and connoting ideas etc.
COMPETING INTERESTS Authors have declared that no competing interests exist. Mhlwatika
References
Antivirals, Biorxiv, None
Barlow, Review of emerging pharmacotherapy for the treatment of coronavirus disease, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Cascella, Features, evaluation and treatment coronavirus (COVID-19)
Chen, The SARS-CoV-2 vaccine pipeline: An overview, Current Tropical Medicine Reports
Ciliberto, Cardone, Boosting the arsenal against COVID-19 through computational drug repurposing, Drug Discovery Today
Ciotti, COVID-19 outbreak: An overview, Chemotherapy
Colson, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents
D'arienzo, Coniglio, Assessment of the SARS-CoV-2 basic reproduction number, R0, based on the early phase of COVID-19 outbreak in Italy
Hamming, Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland
Leung, The difference in the incubation period of 2019 novel coronavirus (SARS-CoV-2) infection between travelers to Hubei and nontravelers: The need for a longer quarantine period, Infection Control & Hospital Epidemiology
Liu, Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2, Journal of Medical Virology
Luo, Clinical pathology of critical patients with novel coronavirus pneumonia (COVID-19), Preprints
Mackenzie, Smith, COVID-19: A novel zoonotic disease caused by a coronavirus from China: what we know and what we don't, Microbiology Australia
Rabaan, SARS-CoV-2, SARS-CoV and MERS-CoV: A comparative overview, Le Infezioni in Medicina
Riva, A Large-scale drug repositioning survey for SARS-CoV-2
Roberts, Hall, Drug absorption, distribution, metabolism, and excretion considerations in critically ill adults, Expert Opinion on Drug Metabolism & Toxicology
Sun, Clinical characteristics of 50466 patients with 2019-nCoV infection, medRxiv
Van Doremalen, Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1, New England Journal of Medicine
Viceconte, Petrosillo, COVID-19 R0: Magic number or conundrum?, Infectious Disease Reports
Wu, Chen, Chan, The outbreak of COVID-19: An overview, Journal of the Chinese Medical Association
Xu, High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa, International Journal of Oral Science
Yao, A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua bing li, xue za zhi= Chinese Journal of Pathology
Zhou, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, The lancet
Zhou, Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery
{ 'indexed': {'date-parts': [[2024, 3, 11]], 'date-time': '2024-03-11T23:35:30Z', 'timestamp': 1710200130255}, 'reference-count': 0, 'publisher': 'Sciencedomain International', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p>After the global pandemic of the new coronavirus, its rapid spread and many victims, ' 'it is necessary to find an effective vaccine or drugs to overcome it. Most specialists ' 'consider that repositioning some medications is the best, fastest and most reliable option ' 'for treating patients with the new coronavirus without delay. One of these drugs was an old ' 'antimalarial drug, hydroxychloroquine. The current review aimed to explore its potential ' 'mechanism, as well as its pharmacokinetics and toxicity, in an attempt to suggest a treatment ' 'protocol for its use in treating the COVID-19 virus effectively and safely. This study ' 'reviewed the published references on the popular search engines as well as the reference ' 'books regarding the pharmacological effects of HCQ. The results of this study suggested the ' 'following practical guidelines to optimize HCQ efficacy and safety in the management of ' 'COVID-19. HQC should be used as early as possible, i.e., once the viral infection is ' 'confirmed or suspected. A loading dose is recommended to be given in 3-4 divided doses to ' 'minimize cardiac toxicity. Maintenance daily dose (divided into two doses), should be ' 'continued until complete remission. Precautions, drug-interaction, contraindications, ' 'variable metabolic pathways in the particular population should be considered. This study ' 'suggests more clinical trials regarding the use of HCQ in the management of early identified ' 'COVID-19 patients under close medical observation to minimize HCQ cardiac toxicity.\xa0\xa0' '</jats:p>', 'DOI': '10.9734/jpri/2020/v32i830468', 'type': 'journal-article', 'created': {'date-parts': [[2020, 6, 2]], 'date-time': '2020-06-02T01:19:05Z', 'timestamp': 1591060745000}, 'page': '29-43', 'source': 'Crossref', 'is-referenced-by-count': 7, 'title': 'Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its ' 'Pharmacological Profile', 'prefix': '10.9734', 'author': [ {'given': 'Ahmed S.', 'family': 'Ali', 'sequence': 'first', 'affiliation': []}, {'given': 'Mahran S.', 'family': 'Abdel-Rahman', 'sequence': 'first', 'affiliation': []}, {'given': 'Riyadh S.', 'family': 'Almalikil', 'sequence': 'first', 'affiliation': []}, {'given': 'Abir S.', 'family': 'Mohamed', 'sequence': 'first', 'affiliation': []}, {'given': 'Khalid A.', 'family': 'Alfaifi', 'sequence': 'first', 'affiliation': []}, {'given': 'Abdelbabgi El.', 'family': 'Fadil', 'sequence': 'first', 'affiliation': []}, {'given': 'Nagla A.', 'family': 'El-Shitany', 'sequence': 'first', 'affiliation': []}, {'given': 'Huda M.', 'family': 'Alkreathy', 'sequence': 'first', 'affiliation': []}], 'member': '4694', 'published-online': {'date-parts': [[2020, 5, 29]]}, 'container-title': 'Journal of Pharmaceutical Research International', 'original-title': [], 'link': [ { 'URL': 'http://www.journaljpri.com/index.php/JPRI/article/download/30468/57153', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://www.journaljpri.com/index.php/JPRI/article/download/30468/57154', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://www.journaljpri.com/index.php/JPRI/article/download/30468/57153', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 10, 6]], 'date-time': '2022-10-06T11:42:51Z', 'timestamp': 1665056571000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journaljpri.com/index.php/JPRI/article/view/1371'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 5, 29]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.9734/jpri/2020/v32i830468', 'relation': {}, 'ISSN': ['2456-9119'], 'subject': [], 'container-title-short': 'JPRI', 'published': {'date-parts': [[2020, 5, 29]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit